Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook


During its first years of existence, DNDi developed an intellectual property (IP) policy to guide its R&D activities and associated contractual agreements with the following objectives:

  • The need to ensure that treatments are ultimately affordable to patients who need them and that access to these treatments is equitable;
  • The desire to develop drugs as public goods when possible (although DNDi will not necessarily be able to control all IP for short- and mid-term projects).

The policy, which reflects the fact that DNDi outputs are likely to have negligible commercial value and that R&D agreements will often be made with public sector entities, calls for a pragmatic approach so that decisions regarding ownership of patents and of licensing terms are made on a case-by-case basis. In building its portfolio, DNDi will continue to negotiate to guarantee the best possible conditions for patients.

Click here to download the full DNDi’s IP policy
Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License